Search clinical trials for: Cetuximab

Total 3051 results

BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
Grupo Español de Linfomas y Transplante Autólogo...
Janssen-Cilag, S.A.

Active, not recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Mantle Cell Lymphoma

Spain
Hoffmann-La Roche

Completed

Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

Follicular Lymphoma

Germany
Masonic Cancer Center, University of Minnesota

Active, not recruiting

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | NHL | High-grade B-cell Lymphoma

United States
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia (VeRitAs)

Chronic Myeloid Leukemia

Italy
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; GELCAB

Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Lymphoma

Spain
Masonic Cancer Center, University of Minnesota

Completed

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Diffuse Large B Cell Non-Hodgkin Lymphoma

United States
Mayo Clinic
University Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaborators

Completed

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Primary Focal Segmental Glomerulosclerosis

Canada, United States
Hospital for Special Surgery, New York
Roche Pharma AG; Genentech, Inc.

Terminated

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis (RENTGPA)

Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

United States
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Anti-CD20 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Withdrawn

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Leukemia
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Lymphoma, Follicular

Spain, Sweden, Canada, Mexico, Czech Republic, France, Switzerland, Australia, Israel, Korea, Republic of, United Kingdom, Italy, Brazil, Finland, Russian Federation, Peru, Denmark, Argentina, Poland, Ecuador, Norway, Slovakia
Stanford University

Terminated

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Lymphoma | Non-Hodgkin's Lymphoma

United States
Celgene Corporation

Completed

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Germany
University Hospital, Rouen

Completed

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (Rituximab2)

Bullous Pemphigoid

France
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.

Completed

Rituximab to Treat Severe Hemophilia A (RICH)

Hemophilia A

United States
Technical University of Munich
University Hospital, Essen; University of Erlangen-Nürnberg; Heinrich-Heine University... and other collaborators

Terminated

Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation (Rituximab 2006)

Renal Transplantation | Transplantation, Kidney | Chronic Allograft Nephropathy | Grafting

Germany
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
University Hospital, Tours

Completed

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases (EvER-ILD)

Lung Disease, Interstitial

France
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
French Innovative Leukemia Organisation

Completed

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Leukemia

France
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

Immune Thrombocytopenic Purpura

Mexico
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
Bicycle Health

Enrolling by invitation

Novel Induction to Buprenorphine/Naloxone

Opioid Use Disorder | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid Misuse

United States
Eli Lilly and Company

Terminated

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States, Australia
M.D. Anderson Cancer Center

Completed

Erlotinib in Combination With Cetuximab

Advanced Cancers

United States
University College, London
AstraZeneca

Not yet recruiting

Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma (CARAMEL)

Mantle Cell Lymphoma
Centre Hospitalier Universitaire de Nice

Recruiting

Personalized Medicine for Membranous Nephropathy (PMMN)

Idiopathic Membranous Nephropathy

France
Takeda

Terminated

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Spain, China, United States, France, United Kingdom, Germany, Canada, Italy, Japan
Hoffmann-La Roche

Completed

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Korea, Republic of
University of Cologne

Completed

HD18 for Advanced Stages in Hodgkins Lymphoma

Hodgkins Lymphoma

Germany
Hoffmann-La Roche

Completed

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Granulomatosis With Polyangiitis

United States, Canada, United Kingdom, Germany, Italy, Serbia, Turkey, France
Hoffmann-La Roche

Completed

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Lymphoma, Non Hodgkin

Spain
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Indolent B-cell Non-Hodgkin's Lymphoma

Japan
University Hospital, Rouen

Completed

Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus (Rituximab 3)

Pemphigus Disease

France
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | MALT Lymphoma

United States
Hoffmann-La Roche

Completed

An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
Hoffmann-La Roche

Completed

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Lymphoma, Follicular

Hungary
Hoffmann-La Roche

Completed

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Follicular Lymphoma

Serbia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient

United States
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
Pfizer
Eli Lilly and Company; Merck Sharp & Dohme LLC; Merck KGaA, Darmstadt, Germany

Recruiting

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)

Metastatic Colorectal Cancer

United States, Denmark, Spain, Australia, France, Italy, Belgium, Slovakia, Canada, Czechia, Germany, Netherlands, Norway, Poland, Sweden, United Kingdom
M.D. Anderson Cancer Center

Completed

Sirolimus and Cetuximab in Advanced Malignancies

Advanced Cancer

United States
Case Comprehensive Cancer Center

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Primary Central Nervous System Non-Hodgkin Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States

Search clinical trials for: Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations